Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.

Authors: Vassel, Faye-Marie; Bian, Ke; Walker, Graham C; Hemann, Michael T

Published In Proc Natl Acad Sci U S A, (2020 11 17)

Abstract: Cisplatin is a standard of care for lung cancer, yet platinum therapy rarely results in substantial tumor regression or a dramatic extension in patient survival. Here, we examined whether targeting Rev7 (also referred to as Mad2B, Mad2L2, and FANCV), a component of the translesion synthesis (TLS) machinery, could potentiate the action of cisplatin in non-small cell lung cancer (NSCLC) treatment. Rev7 loss led to an enhanced tumor cell sensitivity to cisplatin and dramatically improved chemotherapeutic response in a highly drug-resistant mouse model of NSCLC. While cisplatin monotherapy resulted in tumor cell apoptosis, Rev7 deletion promoted a cisplatin-induced senescence phenotype. Moreover, Rev7 deficiency promoted greater cisplatin sensitivity than that previously shown following targeting of other Pol ζ-proteins, suggesting that Pol ζ-dependent and -independent roles of Rev7 are relevant to cisplatin response. Thus, targeting Rev7 may represent a unique strategy for altering and enhancing chemotherapeutic response.

PubMed ID: 33144509 Exiting the NIEHS site

MeSH Terms: Animals; Apoptosis/drug effects; Carcinoma, Non-Small-Cell Lung/drug therapy*; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/metabolism; Cell Line, Tumor; Cisplatin/pharmacology*; DNA Damage; DNA Repair; DNA-Binding Proteins/metabolism; DNA-Directed DNA Polymerase/metabolism; Drug Resistance, Neoplasm; Humans; Lung Neoplasms/drug therapy*; Lung Neoplasms/genetics; Lung Neoplasms/metabolism; Mad2 Proteins/antagonists & inhibitors*; Mad2 Proteins/metabolism; Mice; Mutagenesis; Tumor Cells, Cultured

to Top